Hope S. Rugo, MD, Discusses Future Analyses of Sacituzumab Govitecan in HR+/HER2– Advanced Breast Cancer at ASCO 2022

Video

Hope S. Rugo, MD, FASCO, spoke about future analyses of the phase 3 TROPiCS-02 trial that examined sacituzumab govitecan vs physicians’ choice chemotherapy in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Hope S. Rugo, MD, FASCO, director of Breast Oncology and Clinical Trials Education and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, about additional research surrounding the phase 3 TROPiCS-02 trial (NCT03901339) which is looking at sacituzumab govitecan-hziy (Trodelvy) vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer. She mentioned efficacy of the regimen in patients with HER2-low breast cancer, who might derive benefit from its use. Future presentations will clarify the overall survival benefit of treatment, as there were not enough data at the time of presentation.

Transcript:

For TROPiCS-02, there are additional plans for [more research]. Obviously, we can look at the HER2-low population, which now has become a group where we will have, in the very near future, a treatment option in the second and third lines, or earlier line therapy, with trastuzumab deruxtecan from the DESTINY-Breast04 trial [NCT03734029]. This is very exciting and a highly effective agent in this setting, but that’s an earlier line. It’s helpful to know that in 65% of patients with hormone receptor–positive disease, how many were HER2-low in TROPiCS-02 and how did they do? That’s one analysis.

There are many analyses planned on different biologic- and treatment-related aspects, for example in patients who’ve received prior capecitabine or not. One important secondary end point is overall survival. In the first interim analysis, we didn’t have enough events and there was no significant difference [between treatment arms], but 2 additional analyses are planned. We’ll look for that as well. Then there are other studies looking at sacituzumab govitecan in triple-negative and hormone receptor–positive diseases in combination with checkpoint inhibitors. There’s a post-neoadjuvant trial in high-risk hormone receptor–positive and triple-negative disease being run by the German breast group. [Finally, there is] a neoadjuvant study that started [by examining] sacituzumab govitecan alone and now assessed sacituzumab govitecan and a checkpoint inhibitor.

Reference

Rugo HS, Bardia A, Marme F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol. 2022;40(suppl 17):LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content